Sunday, October 10, 2010
Oncologist Michael Snyderman will present his latest poster on his one-man trial to treat ME/CFS and chronic lymphocytic leukemia with HIV meds at 7 p.m., October 13 at MD Anderson Cancer Center in Houston, Texas. Snyderman, who is XMRV positive, has both ME/CFS and chronic lymphocytic leukemia (CLL), which is relatively common in ME/CFS patients. About 5 percent of ME/CFS patients get it, compared with .02 percent in the general population. Snyderman's taking AZT and raltegravir, two HIV drugs with efficacy against XMRV in test tube studies.
Snyderman continues to feel significantly more energetic than he was prior to initiating antiretroviral therapy. His elevated cytokine signature, particularly interleukin 8, improved on the cocktail and his XMRV viral load dropped. His CLL cells expressed XMRV. Snyderman, however, is concerned that attending the poster presentation may be discouraging for some patients because of the recent upturn in a CLL marker called trisomy 12, which is elevated in 25 percent of patients with CLL. Initially on the drugs, this marker plummeted.
Posted Sunday, October 10, 2010